Which has better earnings and valuation, CRVS or IMRX?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is CRVS or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -38.92% -35.75% Immuneering N/A -31.93% -29.92%

Is MGTX or IMRX more profitable?

Immuneering has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets MeiraGTx -151.12% N/A -54.96% Immuneering N/A -31.93% -29.92%

Which has better earnings and valuation, IMRX or SVRA?

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A Savara N/A N/A -$118.84M -$0.56 N/A

Is IMRX or SVRA more profitable?

Immuneering's return on equity of -31.93% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Savara N/A -87.19% -66.42%

Which has better valuation & earnings, CGEM or IMRX?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is CGEM or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Immuneering N/A -31.93% -29.92%

Which has better earnings & valuation, IMRX or FBRX?

Forte Biosciences is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A Forte Biosciences N/A N/A -$69.38M -$4.64 N/A

Is IMRX or FBRX more profitable?

Immuneering's return on equity of -31.93% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Forte Biosciences N/A -106.17% -85.50%

Immuneering (IMRX) Competitors

$4.13 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.22 +0.09 (+2.30%)

As of 07/31/2026 07:53 PM Eastern

Compare

IMRX vs. CRVS, MGTX, SVRA, CGEM, and FBRX

Should you buy Immuneering stock or one of its competitors? MarketBeat compares Immuneering with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuneering include Corvus Pharmaceuticals (CRVS), MeiraGTx (MGTX), Savara (SVRA), Cullinan Therapeutics (CGEM), and Forte Biosciences (FBRX).

How does Immuneering compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Corvus Pharmaceuticals currently has a consensus target price of $33.33, suggesting a potential upside of 151.38%. Immuneering has a consensus target price of $17.57, suggesting a potential upside of 325.46%. Given Immuneering's higher probable upside, analysts plainly believe Immuneering is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Corvus Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

Immuneering's return on equity of -31.93% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Immuneering	N/A	-31.93%	-29.92%

In the previous week, Corvus Pharmaceuticals had 9 more articles in the media than Immuneering. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 0 mentions for Immuneering. Corvus Pharmaceuticals' average media sentiment score of 1.22 beat Immuneering's score of 0.51 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Positive
Immuneering	Positive

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 14.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Summary

Corvus Pharmaceuticals beats Immuneering on 8 of the 13 factors compared between the two stocks.

How does Immuneering compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

MeiraGTx presently has a consensus price target of $26.00, suggesting a potential upside of 120.53%. Immuneering has a consensus price target of $17.57, suggesting a potential upside of 325.46%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 14.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Immuneering has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$79.76M	13.69	-$114.20M	-$1.48	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Immuneering has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Immuneering	N/A	-31.93%	-29.92%

In the previous week, MeiraGTx had 6 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for MeiraGTx and 0 mentions for Immuneering. MeiraGTx's average media sentiment score of 0.68 beat Immuneering's score of 0.51 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Overall Sentiment
MeiraGTx	Positive
Immuneering	Positive

MeiraGTx has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Summary

Immuneering beats MeiraGTx on 9 of the 14 factors compared between the two stocks.

How does Immuneering compare to Savara?

Immuneering (NASDAQ:IMRX) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Immuneering has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Savara has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

67.7% of Immuneering shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 14.9% of Immuneering shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immuneering currently has a consensus target price of $17.57, suggesting a potential upside of 325.46%. Savara has a consensus target price of $10.14, suggesting a potential upside of 85.77%. Given Immuneering's higher possible upside, equities analysts plainly believe Immuneering is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Immuneering's return on equity of -31.93% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Savara	N/A	-87.19%	-66.42%

In the previous week, Savara had 4 more articles in the media than Immuneering. MarketBeat recorded 4 mentions for Savara and 0 mentions for Immuneering. Savara's average media sentiment score of 1.25 beat Immuneering's score of 0.51 indicating that Savara is being referred to more favorably in the news media.

Company	Overall Sentiment
Immuneering	Positive
Savara	Positive

Summary

Immuneering beats Savara on 7 of the 13 factors compared between the two stocks.

How does Immuneering compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

In the previous week, Cullinan Therapeutics had 11 more articles in the media than Immuneering. MarketBeat recorded 11 mentions for Cullinan Therapeutics and 0 mentions for Immuneering. Immuneering's average media sentiment score of 0.51 beat Cullinan Therapeutics' score of 0.42 indicating that Immuneering is being referred to more favorably in the news media.

Company	Overall Sentiment
Cullinan Therapeutics	Neutral
Immuneering	Positive

Immuneering's return on equity of -31.93% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Immuneering	N/A	-31.93%	-29.92%

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 14.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Cullinan Therapeutics presently has a consensus target price of $32.14, suggesting a potential upside of 94.81%. Immuneering has a consensus target price of $17.57, suggesting a potential upside of 325.46%. Given Immuneering's stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Immuneering beats Cullinan Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Immuneering compare to Forte Biosciences?

Immuneering (NASDAQ:IMRX) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Immuneering's return on equity of -31.93% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Forte Biosciences	N/A	-106.17%	-85.50%

Forte Biosciences is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Immuneering has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, meaning that its share price is 185% more volatile than the broader market.

67.7% of Immuneering shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 14.9% of Immuneering shares are held by company insiders. Comparatively, 4.4% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immuneering currently has a consensus target price of $17.57, suggesting a potential upside of 325.46%. Forte Biosciences has a consensus target price of $72.50, suggesting a potential downside of 5.35%. Given Immuneering's stronger consensus rating and higher probable upside, research analysts clearly believe Immuneering is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Forte Biosciences had 22 more articles in the media than Immuneering. MarketBeat recorded 22 mentions for Forte Biosciences and 0 mentions for Immuneering. Immuneering's average media sentiment score of 0.51 beat Forte Biosciences' score of 0.30 indicating that Immuneering is being referred to more favorably in the media.

Company	Overall Sentiment
Immuneering	Positive
Forte Biosciences	Neutral

Summary

Immuneering beats Forte Biosciences on 11 of the 14 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRX vs. The Competition

Export

Metric	Immuneering	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$267.21M	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-3.53	7.38	282.30	24.66
Price / Sales	N/A	1,200.34	563.12	75.93
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.22	16.96	10.96	6.07
Net Income	-$56.03M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-5.28%	-1.77%	-0.64%	-0.44%
1 Month Performance	-20.42%	-8.39%	-5.23%	-4.81%
1 Year Performance	22.55%	48.40%	61.97%	18.61%

Immuneering Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRX Immuneering	2.6019 of 5 stars	$4.13 flat	$17.57 +325.5%	+22.6%	$267.21M	N/A	N/A	60
CRVS Corvus Pharmaceuticals	3.3156 of 5 stars	$13.16 +1.8%	$33.33 +153.4%	+223.4%	$1.10B	N/A	N/A	30	News Coverage Positive News Upcoming Earnings
MGTX MeiraGTx	3.6136 of 5 stars	$11.82 -3.9%	$26.00 +120.0%	+54.1%	$1.10B	$79.76M	N/A	300
SVRA Savara	2.0463 of 5 stars	$5.28 -2.9%	$10.14 +92.3%	+110.8%	$1.08B	N/A	N/A	20	News Coverage Positive News Gap Up
CGEM Cullinan Therapeutics	2.6727 of 5 stars	$17.54 +0.6%	$32.00 +82.5%	+115.1%	$1.08B	N/A	N/A	30	Positive News Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Competitors

IMRX vs. CRVS, MGTX, SVRA, CGEM, and FBRX

How does Immuneering compare to Corvus Pharmaceuticals?

Summary

How does Immuneering compare to MeiraGTx?

Summary

How does Immuneering compare to Savara?

Summary

How does Immuneering compare to Cullinan Therapeutics?

Summary

How does Immuneering compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuneering (IMRX) Competitors

IMRX vs. CRVS, MGTX, SVRA, CGEM, and FBRX

How does Immuneering compare to Corvus Pharmaceuticals?

Do analysts rate CRVS or IMRX?

Which has more risk and volatility, CRVS or IMRX?

Is CRVS or IMRX more profitable?

Does the media favor CRVS or IMRX?

Do institutionals & insiders believe in CRVS or IMRX?

Which has better earnings and valuation, CRVS or IMRX?

Summary

How does Immuneering compare to MeiraGTx?

Do analysts prefer MGTX or IMRX?

Do institutionals and insiders hold more shares of MGTX or IMRX?

Which has better earnings & valuation, MGTX or IMRX?

Is MGTX or IMRX more profitable?

Does the media prefer MGTX or IMRX?

Which has more volatility & risk, MGTX or IMRX?

Summary

How does Immuneering compare to Savara?

Which has more volatility & risk, IMRX or SVRA?

Which has better earnings and valuation, IMRX or SVRA?

Do institutionals and insiders hold more shares of IMRX or SVRA?

Do analysts prefer IMRX or SVRA?

Is IMRX or SVRA more profitable?

Does the media refer more to IMRX or SVRA?

Summary

How does Immuneering compare to Cullinan Therapeutics?

Which has better valuation & earnings, CGEM or IMRX?

Does the media favor CGEM or IMRX?

Is CGEM or IMRX more profitable?

Do institutionals & insiders believe in CGEM or IMRX?

Which has more volatility and risk, CGEM or IMRX?

Do analysts rate CGEM or IMRX?

Summary

How does Immuneering compare to Forte Biosciences?

Is IMRX or FBRX more profitable?

Which has better earnings & valuation, IMRX or FBRX?

Which has more risk & volatility, IMRX or FBRX?

Do institutionals & insiders hold more shares of IMRX or FBRX?

Do analysts prefer IMRX or FBRX?

Does the media refer more to IMRX or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools